Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L. Hijazi Z, et al. Among authors: wallentin l. Am Heart J. 2017 Aug;190:94-103. doi: 10.1016/j.ahj.2017.06.001. Epub 2017 Jun 6. Am Heart J. 2017. PMID: 28760218 Clinical Trial.
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Wallentin L, Bergstrand L, Dellborg M, Fellenius C, Granger CB, Lindahl B, Lins LE, Nilsson T, Pehrsson K, Siegbahn A, Swahn E. Wallentin L, et al. Eur Heart J. 2003 May;24(10):897-908. doi: 10.1016/s0195-668x(03)00006-x. Eur Heart J. 2003. PMID: 12714021 Clinical Trial.
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Circulation. 2003 Jul 22;108(3):275-81. doi: 10.1161/01.CIR.0000079170.10579.DC. Epub 2003 Jul 7. Circulation. 2003. PMID: 12847065 Clinical Trial.
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
James SK, Siegbahn A, Armstrong P, Barnathan E, Califf R, Simoons ML, Wallentin L. James SK, et al. Among authors: wallentin l. Am Heart J. 2004 Feb;147(2):267-74. doi: 10.1016/j.ahj.2003.09.014. Am Heart J. 2004. PMID: 14760324 Clinical Trial.
Natriuretic peptides in unstable coronary artery disease.
Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, Wallentin L. Jernberg T, et al. Among authors: wallentin l. Eur Heart J. 2004 Sep;25(17):1486-93. doi: 10.1016/j.ehj.2004.06.017. Eur Heart J. 2004. PMID: 15342167 Review.
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial.
Björklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, Van De Werf F, Wallentin L; Swedish ASSENT-2; RIKS-HIA Investigators. Björklund E, et al. Among authors: wallentin l. Am Heart J. 2004 Oct;148(4):566-73. doi: 10.1016/j.ahj.2004.04.014. Am Heart J. 2004. PMID: 15459584
835 results